1 BTC
=
- USD
Exelixis Inc
As of May 30, 2026 at 24:05 UTC
Chart
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Market Statistics
Trading Metrics
How to Buy EXEL
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy EXEL
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesExelixis, a biotech company focused on cancer medicines, could potentially double by 2031. While its main product Cabometyx will face generic competition by early 2030, the company's promising pipeline candidate zanzalintinib could reach peak sales of $5 billion across multiple cancer indications, positioning it as a strong successor to drive future growth.
Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial failed to meet primary endpoints for a triplet therapy combining Keytruda, Lenvima, and Welireg for advanced clear cell renal cell carcinoma. The failure caused Merck shares to fall 4.08%. However, the FDA approved Merck's new HIV treatment Idvynso on the same day, and analysts suggest alternative treatment strategies may still be viable.
The article recommends three healthcare stocks trading under $50: Pfizer (PFE) at $27.45 with a low forward P/E of 9x and a strong oncology pipeline; Novo Nordisk (NVO) at $38.43 positioned to capitalize on the expanding weight-loss drug market with products like Wegovy; and Exelixis (EXEL) at $41.80, a focused oncology player with the successful Cabometyx therapy and promising pipeline candidates like zanzalintinib.
Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.
InSilico Medicine, fresh from Hong Kong's biggest 2025 IPO raising HK$2.28 billion, announced a multi-year drug discovery partnership with French pharmaceutical company Servier worth up to $888 million. The deal leverages InSilico's AI platform for cancer drug development. Despite strong investor backing and rapid pipeline progress, the company faces profitability challenges with volatile revenue heavily dependent on partnership payments.
